China Phase III Results Boost Global Prospects For HUTCHMED ITP Drug

 
• By Dexter Jie Yan
  
Generate a summary of this article
Listen to this article
Beta

The Phase III ESLIM-01 study with HUTCHMED’s Syk inhibitor sovleplenib met its primary endpoint, demonstrating a 48.4% durable response rate for chronic immune thrombocytopenia, significantly higher than placebo. Global development appears to be accelerating and a multinational dose-finding Phase Ib study has also been initiated.

Blood disorder
Immune thrombocytopenia is a rare autoimmune blood disorder • Source: Shutterstock

HUTCHMED (China) Limited looks set to step up its first major effort to gain a foothold in the US autoimmune space after positive results from the China-only Phase III ESLIM-01 clinical study with sovleplenib in heavily pretreated patients with chronic primary immune thrombocytopenia (ITP), a rare autoimmune blood disorder. 

Key Takeaways

  • Results from the Phase III ESLIM-01 study with HUTCHMED'S sovleplenib, a novel spleen tyrosine kinase (Syk) inhibitor, show a significantly higher durable response rate than placebo in heavily pretreated patients with chronic primary immune thrombocytopenia.

Clinical outcomes from the 188-patient study showed the novel spleen tyrosine kinase (Syk) inhibitor met the primary endpoint of a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

Embracing China’s Brave New Pharmaceutical World!

 
• By Ellon Xu, Philip Leung, and Grace Shieh

Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.